Lipocine announces positive lpcn 1144 nash open label extension study results

Lpcn 1144 was well tolerated over 72-week exposure with no observed safety signals liver injury markers were reduced and maintained with extended lpcn 1144 treatment observed liver histology improvements support further development salt lake city , may 12, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology to develop innovative products to treat neuroendocrine and metabolic disorders, announces positive topline results from its open label extension study, ole.  lpcn 1144 comprises an orally delivered prodrug of testosterone.
LPCN Ratings Summary
LPCN Quant Ranking